References
[1]Zhang Y, Chen X, Liang X, et al. Altered Weibull Degree Distribution in Resting-State Functional Brain Networks Is Associated With Cognitive Decline in Mild Cognitive Impairment[J]. Front Aging Neurosci. 2020, 12(599112). Doi:10.3389/fnagi.2020.599112.
[2]RC P. Mild cognitive impairment.[J]. N Engl J Med. 2011, 2011 Jun 9;364(23):2227-34. Doi: 10.1056/NEJMcp0910237.
[3]Anderson N D. State of the science on mild cognitive impairment (MCI)[J]. CNS Spectr. 2019, 24(1): 78-87. Doi:10.1017/S1092852918001347.
[4]Mitchell A J,Shiri-Feshki M. Rate of progression of mild cognitive impairment to dementia - meta-analysis of 41 robust inception cohort studies[J]. Acta Psychiatrica Scandinavica. 2009, 119(4): 252-265. Doi:10.1111/j.1600-0447.2008.01326.x.
[5]Weissberger G, Gibson K, Nguyen C, et al. Neuropsychological case report of MCI reversion at one-year follow-up[J]. Applied Neuropsychology: Adult. 2018, 27(3): 284-293. Doi:10.1080/23279095.2018.1519510.
[6]Canevelli M, Grande G, Lacorte E, et al. Spontaneous Reversion of Mild Cognitive Impairment to Normal Cognition: A Systematic Review of Literature and Meta-Analysis[J]. J Am Med Dir Assoc. 2016, 17(10): 943-8. Doi:10.1016/j.jamda.2016.06.020.
[7]Colomina M T,Peris-Sampedro F. Aluminum and Alzheimer's Disease[J]. Adv Neurobiol. 2017, 18(183-197. Doi:10.1007/978-3-319-60189-2_9.
[8]Exley C. Human exposure to aluminium[J]. Environ Sci Process Impacts. 2013, 15(10): 1807-1816. Doi:10.1039/c3em00374d.
[9]Klotz K, Weistenhofer W, Neff F, et al. The Health Effects of Aluminum Exposure[J]. Dtsch Arztebl Int. 2017, 114(39): 653-659. Doi:10.3238/arztebl.2017.0653.
[10]Virk S A,Eslick G D. Occupational Exposure to Aluminum and Alzheimer Disease: A Meta-Analysis[J]. J Occup Environ Med. 2015, 57(8): 893-6. Doi:10.1097/JOM.0000000000000487.
[11]Bagepally B S, Balachandar R, Kalahasthi R, et al. Association between aluminium exposure and cognitive functions: A systematic review and meta-analysis[J]. Chemosphere. 2021, 268. Doi:10.1016/j.chemosphere.2020.128831.
[12]Liu S, Buch S, Chen Y, et al. Susceptibility-weighted imaging: current status and future directions[J]. NMR Biomed. 2017, 30(4): 10.1002/nbm.3552. Doi:10.1002/nbm.3552.
[13]Gao L, Jiang Z, Cai Z, et al. Brain iron deposition analysis using susceptibility weighted imaging and its association with body iron level in patients with mild cognitive impairment[J]. Mol Med Rep. 2017, 16(6): 8209-8215. Doi:10.3892/mmr.2017.7668.
[14]Kirsch W, McAuley G, Holshouser B, et al. Serial susceptibility weighted MRI measures brain iron and microbleeds in dementia[J]. J Alzheimers Dis. 2009, 17(3): 599-609. Doi:10.3233/JAD-2009-1073.
[15]Liu C, Li W, Tong K A, et al. Susceptibility-weighted imaging and quantitative susceptibility mapping in the brain[J]. J Magn Reson Imaging. 2015, 42(1): 23-41. Doi:10.1002/jmri.24768.
[16]Ippoliti M, Adams L C, Winfried B, et al. Quantitative susceptibility mapping across two clinical field strengths: Contrast-to-noise ratio enhancement at 1.5T[J]. J Magn Reson Imaging. 2018, 48(5): 1410-1420. Doi:10.1002/jmri.26045.
[17]Deistung A, Schweser F,Reichenbach J R. Overview of quantitative susceptibility mapping[J]. NMR Biomed. 2017, 30(4). Doi:10.1002/nbm.3569.
[18]Haacke E M, Liu S, Buch S, et al. Quantitative susceptibility mapping: current status and future directions[J]. Magnetic Resonance Imaging. 2015, 33(1): 1-25. Doi:10.1016/j.mri.2014.09.004.
[19]Wang Y, Spincemaille P, Liu Z, et al. Clinical quantitative susceptibility mapping (QSM): Biometal imaging and its emerging roles in patient care[J]. Journal of Magnetic Resonance Imaging. 2017, 46(4): 951-971. Doi:10.1002/jmri.25693.
[20]Vinayagamani S, Sheelakumari R, Sabarish S, et al. Quantitative Susceptibility Mapping: Technical Considerations and Clinical Applications in Neuroimaging[J]. J Magn Reson Imaging. 2021, 53(1): 23-37. Doi:10.1002/jmri.27058.
[21]Bo Z, Tianjing Z, Jiafei C, et al. Quantitative susceptibility mapping of the brain iron deposition in patients with mild cognitive impairment[J]. International Journal of Medical Radiology. 2019, 42(01): 32-36. Doi:10.19300/j.2019.L6218.
[22]Yang Q, Zhou L, Liu C, et al. Brain iron deposition in type 2 diabetes mellitus with and without mild cognitive impairment—an in vivo susceptibility mapping study[J]. Brain Imaging and Behavior. 2018, 12(5): 1479-1487. Doi:10.1007/s11682-017-9815-7.
[23]Langa K M, Levine D A. The diagnosis and management of mild cognitive impairment: a clinical review[J]. JAMA. 2014, 312(23): 2551-61. Doi:10.1001/jama.2014.13806.
[24]Vega J N,Newhouse P A. Mild cognitive impairment: diagnosis, longitudinal course, and emerging treatments[J]. Curr Psychiatry Rep. 2014, 16(10): 490. Doi:10.1007/s11920-014-0490-8.
[25]Lu X, Liang R, Jia Z, et al. Cognitive disorders and tau-protein expression among retired aluminum smelting workers[J]. J Occup Environ Med. 2014, 56(2): 155-60. Doi:10.1097/JOM.0000000000000100.
[26]Gauthier S, Reisberg B, Zaudig M, et al. Mild cognitive impairment[J]. The Lancet. 2006, 367(9518): 1262-1270. Doi:10.1016/s0140-6736(06)68542-5.
[27]Walton J R,Wang M X. APP expression, distribution and accumulation are altered by aluminum in a rodent model for Alzheimer's disease[J]. J Inorg Biochem. 2009, 103(11): 1548-54. Doi:10.1016/j.jinorgbio.2009.07.027.
[28]Mufson E J, Binder L, Counts S E, et al. Mild cognitive impairment: pathology and mechanisms[J]. Acta Neuropathol. 2012, 123(1): 13-30. Doi:10.1007/s00401-011-0884-1.
[29]Kim H-G, Park S, Rhee H Y, et al. Quantitative susceptibility mapping to evaluate the early stage of Alzheimer's disease[J]. NeuroImage: Clinical. 2017, 16: 429-438. Doi:10.1016/j.nicl.2017.08.019.
[30]Hwang E J, Kim H G, Kim D, et al. Texture analyses of quantitative susceptibility maps to differentiate Alzheimer's disease from cognitive normal and mild cognitive impairment[J]. Med Phys. 2016, 43(8): 4718. Doi:10.1118/1.4958959.
[31]Acosta-Cabronero J, Williams G B, Cardenas-Blanco A, et al. In vivo quantitative susceptibility mapping (QSM) in Alzheimer's disease[J]. PLoS One. 2013, 8(11): e81093. Doi:10.1371/journal.pone.0081093.
[32]Shuang X, Chao C, Wen S, et al. Preliminary study of distribution and age-related changes of iron-content in the brain using MR quantitative susceptibility mapping[J]. Chinese Journal of Radiology. 2014, 48(9): 730-735. Doi:10.3760/cma.j.issn.1005-1201.2014.09.008.
[33]John B. Iron deficiency alters brain development and functioning[J]. J Nutr. 2003, 133(5 Suppl 1): 1468S-72S. Doi:10.1093/jn/133.5.1468S.
[34]Polizzi S P E, Ferrara M, Bugiani M, Papaleo A, Albera R, Palmi S. Neurotoxic effects of aluminium among foundry workers and Alzheimer's disease[J]. Neurotoxicology. 2002, 6(23): 761-74. Doi: 10.1016/S0161-813X(02)00097-9.
[35]Rondeau V, Commenges D, Jacqmin-Gadda H, et al. Relation between aluminum concentrations in drinking water and Alzheimer's disease: an 8-year follow-up study[J]. Am J Epidemiol. 2000, 152(1): 59-66. Doi: 10.1093/aje/152.1.59.